Ransom Advisory Ltd Buys New Shares in Danaher Corporation $DHR

Key Points

• Ransom Advisory Ltd invested $536,000 to purchase 2,617 shares of Danaher Corporation, showcasing interest from institutional investors in the stock.
• Danaher recently posted quarterly earnings of $1.80 per share, exceeding estimates, and reported a revenue of $5.94 billion, up 3.4% year-over-year.
• The stock has a current price target of approximately $246.35 from analysts, reflecting a consensus rating of "Moderate Buy" with 17 analysts recommending a buy.

Ransom Advisory Ltd acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,617 shares of the conglomerate's stock, valued at approximately $536,000.

Other hedge funds also recently made changes to their positions in the company. Anchor Investment Management LLC raised its position in Danaher by 73.7% during the first quarter. Anchor Investment Management LLC now owns 8,607 shares of the conglomerate's stock worth $1,764,000 after acquiring an additional 3,652 shares during the last quarter. Ilmarinen Mutual Pension Insurance Co lifted its position in Danaher by 10.5% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 94,500 shares of the conglomerate's stock valued at $19,373,000 after buying an additional 9,000 shares in the last quarter. Plato Investment Management Ltd lifted its position in Danaher by 0.5% during the first quarter. Plato Investment Management Ltd now owns 13,030 shares of the conglomerate's stock valued at $2,700,000 after buying an additional 59 shares in the last quarter. SCS Capital Management LLC acquired a new position in shares of Danaher during the first quarter worth $711,000. Finally, Woodline Partners LP raised its holdings in Danaher by 11.8% in the first quarter. Woodline Partners LP now owns 463,914 shares of the conglomerate's stock valued at $95,102,000 after acquiring an additional 49,143 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Down 0.8%

Shares of DHR stock traded down $1.51 during trading hours on Monday, reaching $188.54. 2,003,095 shares of the company's stock were exchanged, compared to its average volume of 4,126,743. The stock's 50 day moving average is $201.21 and its 200-day moving average is $198.78. The company has a market cap of $135.00 billion, a price-to-earnings ratio of 40.06, a P/E/G ratio of 2.65 and a beta of 0.75. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on DHR shares. Guggenheim reiterated a "buy" rating and set a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Wells Fargo & Company lowered their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research report on Tuesday, September 2nd. Finally, Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.